A recombinant influenza a virus expressing domain III of west nile virus induces protective immune responses against influenza and west nile virus

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Martina, Byron E E ^a   van den Doel, Petra ^a   Koraka, Penelope ^a   van Amerongen, Geert ^b   Spohn, Gunther ^c   Haagmans, Bart L ^a   Provacia, Lisette B V ^a   Osterhaus, Albert D M E ^a   Rimmelzwaan, Guus F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INFLUENZA VIRUS EXPRESSING DOMAIN III OF THE WEST NILE FLAVIVIRUS GLYCOPROTEIN E VACCINE; RECOMBINANT INFLUENZA VIRUS EXPRESSING GREEN FLUORESCENT PROTEIN VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; INFLUENZA VACCINE; VIRUS PROTEIN; WEST NILE VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS TITRATION; WEST NILE FLAVIVIRUS; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DOG; GENETIC RECOMBINATION; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A; ORTHOMYXOVIRUS INFECTION; PROTEIN TERTIARY STRUCTURE; SPECIES DIFFERENCE; TREATMENT OUTCOME; VACCINATION; VIROLOGY; WEIGHT REDUCTION; WEST NILE FEVER;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; WEST NILE VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DOGS; HUMANS; IMMUNITY; IMMUNITY, HUMORAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN STRUCTURE, TERTIARY; RECOMBINATION, GENETIC; SPECIES SPECIFICITY; TREATMENT OUTCOME; VACCINATION; VIRAL PROTEINS; WEIGHT LOSS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 79955637320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018995     Document Type: Article

References (58)

1. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, et al. (2001) Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358: 261-264.
2. Pawelec G, Rehbein A, Haehnel K, Merl A, Adibzadeh M, (1997) Human T-cell clones in long-term culture as a model of immunosenescence. Immunol Rev 160: 31-42.
3. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, et al. (1984) Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 28: 47-55.
4. Fleming DM, Elliot AJ, (2008) Lessons from 40 years' surveillance of influenza in England and Wales. Epidemiol Infect 136: 866-875.
5. Gubler DJ, (2007) The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 45: 1039-1046.
6. Kramer LD, Styer LM, Ebel GD, (2008) A global perspective on the epidemiology of West Nile virus. Annu Rev Entomol 53: 61-81.
7. Grazzini G, Liumbruno GM, Pupella S, Silvestri AR, Randi V, et al. (2008) West Nile virus in Italy: a further threat to blood safety, a further challenge to the blood system. Blood Transfus 6: 235-237.
8. Rossini G, Cavrini F, Pierro A, Macini P, Finarelli A, et al. (2008) First human case of West Nile virus neuroinvasive infection in Italy, September 2008- case report. Euro Surveill 13.
9. Figuerola J, Soriguer R, Rojo G, Gomez Tejedor C, Jimenez-Clavero MA, (2007) Seroconversion in wild birds and local circulation of West Nile virus, Spain. Emerg Infect Dis 13: 1915-1917.
10. Couissinier-Paris P, (2006) West Nile virus in Europe and Africa: still minor pathogen, or potential threat to public health? Bull Soc Pathol Exot 99: 348-354.
11. Chu JH, Chiang CC, Ng ML, (2007) Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 178: 2699-2705.
12. Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, et al. (2008) Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26: 153-157.
13. Coutant F, Frenkiel MP, Despres P, Charneau P, (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE 3: e3973.
14. Bonafe N, Rininger JA, Chubet RG, Foellmer HG, Fader S, et al. (2009) A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 27: 213-222.
15. Lim CK, Takasaki T, Kotaki A, Kurane I, (2008) Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 374: 60-70.
16. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828-11839.
17. Watts DM, Tesh RB, Siirin M, Rosa AT, Newman PC, et al. (2007) Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25: 2913-2918.
18. Seregin A, Nistler R, Borisevich V, Yamshchikov G, Chaporgina E, et al. (2006) Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives. Virology 356: 115-125.
19. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, et al. (2005) Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191: 207-214.
20. Yamshchikov G, Borisevich V, Seregin A, Chaporgina E, Mishina M, et al. (2004) An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330: 304-312.
21. McMurtrey CP, Lelic A, Piazza P, Chakrabarti AK, Yablonsky EJ, et al. (2008) Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci U S A 105: 2981-2986.
22. Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, et al. (2006) Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol 80: 11000-11008.
23. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, et al. (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764-769.
24. Li L, Barrett AD, Beasley DW, (2005) Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335: 99-105.
25. Chang YS, van Hal SJ, Spencer PM, Gosbell IB, Collett PW, Comparison of adult patients hospitalised with pandemic (H1N1) 2009 influenza and seasonal influenza during the "PROTECT" phase of the pandemic response. Med J Aust 192: 90-93.
26. Tregoning JS, Schwarze J, Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23: 74-98.
27. Rimmelzwaan GF, Nieuwkoop NJ, de Mutsert G, Boon AC, Kuiken T, et al. (2007) Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Res 129: 175-181.
28. de Wit E, Spronken MI, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. (2004) Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res 103: 155-161.
29. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG, (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97: 6108-6113.
30. de Wit E, Spronken MI, Vervaet G, Rimmelzwaan GF, Osterhaus AD, et al. (2007) A reverse-genetics system for Influenza A virus using T7 RNA polymerase. J Gen Virol 88: 1281-1287.
31. Masurel N, Ophof P, de Jong P, (1981) Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond) 87: 201-209.
32. Engle MJ, Diamond MS, (2003) Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 77: 12941-12949.
33. Pierson TC, Diamond MS, (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.
34. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS, (2008) The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26: 2020-2033.
35. Beasley DW, Barrett AD, (2002) Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76: 13097-13100.
36. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149-12159.
37. Sanchez MD, Pierson TC, McAllister D, Hanna SL, Puffer BA, et al. (2005) Characterization of neutralizing antibodies to West Nile virus. Virology 336: 70-82.
38. Brien JD, Uhrlaub JL, Nikolich-Zugich J, (2008) West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol 181: 8568-8575.
39. Sitati EM, Diamond MS, (2006) CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 80: 12060-12069.
40. Shrestha B, Diamond MS, (2004) Role of CD8+ T cells in control of West Nile virus infection. J Virol 78: 8312-8321.
41. Shrestha B, Samuel MA, Diamond MS, (2006) CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol 80: 119-129.
42. Wang Y, Lobigs M, Lee E, Koskinen A, Mullbacher A, (2006) CD8(+) T cell-mediated immune responses in West Nile virus (Sarafend strain) encephalitis are independent of gamma interferon. J Gen Virol 87: 3599-3609.
43. Wang Y, Lobigs M, Lee E, Mullbacher A, (2003) CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77: 13323-13334.
44. Castrucci MR, Hou S, Doherty PC, Kawaoka Y, (1994) Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol 68: 3486-3490.
45. Ferko B, Katinger D, Grassauer A, Egorov A, Romanova J, et al. (1998) Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 178: 1359-1368.
46. Li S, Polonis V, Isobe H, Zaghouani H, Guinea R, et al. (1993) Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol 67: 6659-6666.
47. Li ZN, Mueller SN, Ye L, Bu Z, Yang C, et al. (2005) Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity. J Virol 79: 10003-10012.
48. Shinya K, Fujii Y, Ito H, Ito T, Kawaoka Y, (2004) Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine. J Virol 78: 3083-3088.
49. Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV, (2005) Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 23: 2922-2927.
50. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
51. Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, et al. (2009) RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27: 5550-5553.
52. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, et al. (2004) ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78: 12497-12507.
53. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, et al. (2006) A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 8: 265-274.
54. Iyer AV, Pahar B, Boudreaux MJ, Wakamatsu N, Roy AF, et al. (2009) Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 27: 893-903.
55. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW, (2002) West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 99: 3036-3041.
56. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL, (2007) Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119: 1076-1082.
57. Giri PK, Sable SB, Verma I, Khuller GK, (2005) Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol Med Microbiol 45: 87-93.
58. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM, (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351: 2295-2301.